These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 33338945

  • 1. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
    Correa-Díaz EP, Torres-Herrán GE, Miño Zambrano JE, Paredes-Gonzalez V, Caiza-Zambrano FJ.
    Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J, Yu H, Wang H, Zhang X, Feng K.
    J Neuroimmunol; 2022 Feb 15; 363():577790. PubMed ID: 34959021
    [Abstract] [Full Text] [Related]

  • 3. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y, Wang CJ, Wang BJ, Zeng ZL, Guo SG.
    J Neurol Sci; 2018 Feb 15; 385():192-197. PubMed ID: 29406904
    [Abstract] [Full Text] [Related]

  • 4. Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder.
    Gomez-Figueroa E, Noriega-Morales G, Casallas-Vanegas A, Zabala-Angeles I, Garcia-Estrada C, Neri D, Sarachaga AJ, Rivas-Alonso V, Corona-Vazquez T, Flores-Rivera J.
    Clin Neurol Neurosurg; 2020 Sep 15; 196():106007. PubMed ID: 32559706
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: Experience from a national health institute in México.
    Casallas-Vanegas A, Gomez-Figueroa E, de Saráchaga AJ, Zabala-Angeles I, García-Estrada C, Salado-Burbano JC, DiazGranados-Palacio MC, Corona-Vázquez T, de Jesús Flores-Rivera J, Rivas-Alonso V.
    J Neurol Sci; 2020 Dec 15; 419():117204. PubMed ID: 33161302
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Wang Y, Chang H, Zhang X, Yin L.
    Mult Scler Relat Disord; 2021 May 15; 50():102843. PubMed ID: 33609924
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis.
    Gao F, Chai B, Gu C, Wu R, Dong T, Yao Y, Zhang Y.
    BMC Neurol; 2019 Mar 06; 19(1):36. PubMed ID: 30841862
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder.
    Ongphichetmetha T, Jitprapaikulsan J, Siritho S, Rattanathamsakul N, Detweeratham T, Prayoonwiwat N.
    Sci Rep; 2024 Feb 12; 14(1):3503. PubMed ID: 38347079
    [Abstract] [Full Text] [Related]

  • 15. Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder.
    Shi B, Zhao M, Qiao L, Huang F, Zhou S, Wei Y, Wang J, Wang N.
    Mult Scler Relat Disord; 2021 Sep 12; 54():103143. PubMed ID: 34273608
    [Abstract] [Full Text] [Related]

  • 16. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME, Andreadou E, Koutsis G, Koutoulidis V, Anagnostouli M, Katsika P, Evangelopoulos DS, Evdokimidis I, Kilidireas C.
    J Neurol Sci; 2017 Jan 15; 372():92-96. PubMed ID: 28017256
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
    Spagni G, Sun B, Monte G, Sechi E, Iorio R, Evoli A, Damato V.
    J Neurol Neurosurg Psychiatry; 2023 Jan 15; 94(1):62-69. PubMed ID: 36283808
    [Abstract] [Full Text] [Related]

  • 18. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.
    Kunchok A, Malpas C, Nytrova P, Havrdova EK, Alroughani R, Terzi M, Yamout B, Hor JY, Karabudak R, Boz C, Ozakbas S, Olascoaga J, Simo M, Granella F, Patti F, McCombe P, Csepany T, Singhal B, Bergamaschi R, Fragoso Y, Al-Harbi T, Turkoglu R, Lechner-Scott J, Laureys G, Oreja-Guevara C, Pucci E, Sola P, Ferraro D, Altintas A, Soysal A, Vucic S, Grand'Maison F, Izquierdo G, Eichau S, Lugaresi A, Onofrj M, Trojano M, Marriott M, Butzkueven H, Kister I, Kalincik T.
    Mult Scler Relat Disord; 2020 Feb 15; 38():101868. PubMed ID: 31877445
    [Abstract] [Full Text] [Related]

  • 19. Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study.
    Cabre P, Mejdoubi M, Jeannin S, Merle H, Plumelle Y, Cavillon G, Smadja D, Marignier R, Francophone Society of Multiple Sclerosis and OFSEP investigators.
    J Neurol; 2018 Apr 15; 265(4):917-925. PubMed ID: 29455361
    [Abstract] [Full Text] [Related]

  • 20. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
    Kim SH, Jeong IH, Hyun JW, Joung A, Jo HJ, Hwang SH, Yun S, Joo J, Kim HJ.
    JAMA Neurol; 2015 Sep 15; 72(9):989-95. PubMed ID: 26167726
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.